ROS1 and non-small cell lung carcinoma: Crizotinib was recently approved by the FDA for patients with advanced ROS1-positive NSCLC [12]; therefore, detection of ROS1 gene rearrangements is critical for the optimal treatment of ROS1-positive NSCLC patients.